乾癬性関節炎市場 - KOLの考察

当レポートでは、乾癬性関節炎市場について調査分析し、上市済みの治療法とパイプラインにある治療法に対するKOLの考察を提供しています。

目次

エグゼクティブサマリー

乾癬性関節炎の現在と将来の治療アルゴリズム

調査目的

承認済みの医薬品

• 抗腫瘍壊死因子剤
  • 重要な考察のまとめ
• インターロイキン17阻害薬
  • Cosentyx (secukinumab; Novartis)
  • Taltz (ixekizumab; Lilly)
• インターロイキン12/23、インターロイキン23阻害薬
  • Stelara (ustekinumab; Janssen)
  • Tremfya (guselkumab; Janssen)
  • Skyrizi (risankizumab; AbbVie/Boehringer Ingelheim)
• ヤヌスキナーゼ（JAK）阻害薬
  • Xeljanz (tofacitinib; Pfizer)
  • Rinvoq (upadacitinib; AbbVie)
• 4型環状ヌクレオチドホスホジエステラーゼ阻害薬
  • Otezla (apremilast; Amgen)
• T細胞活性化阻害薬
  • Orencia (abatacept; Bristol Myers Squibb)

パイプライン医薬品

• インターロイキン17阻害薬
  • Bimzelx (bimekizumab; UCB)
  • Izokibep (Affibody/Acelyrin)
  • Sonelokimab (MoonLake Immunotherapeutics)
• インターロイキン23阻害薬
  • Ilumya/Ilumetri (tildrakizumab; Almirall/Sun Pharmaceutical)
• チロシンキナーゼ2（TYK2）阻害薬
  • Sotyktu (deucravacitinib; Bristol Myers Squibb)
  • TAK-279 (Takeda)
• TYK2/JAK-1阻害薬
  • Brepocitinib (Priovant Therapeutics)
• マイトジェン活性化プロテインキナーゼ活性化プロテインキナーゼ-2阻害薬
  • Zunsemetinib (Aclaris Therapeutics)

乾癬性関節炎治療における将来の動向と機会

付録

ニュース

What clinical and commercial factors are influencing KOLs' prescribing decisions for Novartis' Cosentyx and Lilly's Taltz anti-IL-17 therapies? In the IL-23 inhibitor sector, how do rheumatologists assess the clinical advantages of Janssen's Tremfya and AbbVie/Boehringer Ingelheim's Skyrizi in patients with severe skin disease who have milder arthritis or IBD? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the following KOL Bulletins via the Attachments area.

• 15 Jun 23 KOL Bulletin -- Views on the long-term Phase III data for UCB'S Bimzelx

• 16 Jun 23 KOL Bulletin -- Views on post-hoc analysis of Phase III COSMOS data for Janssen's Tremfya

Table of Contents

Executive summary

Current and future treatment algorithm for psoriatic arthritis

Research objectives

Approved drugs

• Anti-tumour necrosis factor agents
  • Key insights summary
• Interleukin-17 inhibitors
  • Cosentyx (secukinumab; Novartis)
  • Taltz (ixekizumab; Lilly)
• Interleukin-12/23 and interleukin-23 inhibitors
  • Stelara (ustekinumab; Janssen)
  • Tremfya (guselkumab; Janssen)
  • Skyrizi (risankizumab; AbbVie/Boehringer Ingelheim)
• Janus kinase (JAK) inhibitors
  • Xeljanz (tofacitinib; Pfizer)
  • Rinvoq (upadacitinib; AbbVie)
• Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Otezla (apremilast; Amgen)
• T-cell activation inhibitors
  • Orencia (abatacept; Bristol Myers Squibb)

Pipeline drugs

• Interleukin-17 inhibitors
  • Bimzelx (bimekizumab; UCB)
  • Izokibep (Affibody/Acelyrin)
  • Sonelokimab (MoonLake Immunotherapeutics)
• Interleukin-23 inhibitors
  • Ilumya/Ilumetri (tildrakizumab; Almirall/Sun Pharmaceutical)
• Tyrosine kinase 2 (TYK2) inhibitors
  • Sotyktu (deucravacitinib; Bristol Myers Squibb)
  • TAK-279 (Takeda)
• TYK2/JAK-1 inhibitor
  • Brepocitinib (Priovant Therapeutics)
• Mitogen-activated protein kinase-activated protein kinase-2 inhibitor
  • Zunsemetinib (Aclaris Therapeutics)

Future trends and opportunities in psoriatic arthritis treatment

Appendix

• KOL details
  • KOLs from the USA
  • KOLs from Europe

News